Literature DB >> 10329404

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

K Kato1, H Satoh, Y Endo, D Yamada, S Midorikawa, W Sato, K Mizuno, T Fujita, K Tsukamoto, T Watanabe.   

Abstract

The effect of peroxisome proliferator-activated receptor (PPAR) gamma activators, thiazolidinediones, on plasminogen activator type 1 (PAI-1) was examined in cultured human umbilical vein endothelial cells (HUVEC). Tumor necrosis factor alpha (TNF-alpha) enhanced PAI-1 secretion and mRNA expression by approximately 2-fold. The thiazolidinediones, troglitazone and pioglitazone, decreased basal and TNF-alpha-stimulated PAI-1 secretion and mRNA expression in HUVEC in a dose-dependent fashion. PPARgamma mRNA in HUVEC could be detected by reverse transcriptase-polymerase chain reaction using specific primers. These results suggest that PPARgamma may regulate PAI-1 expression in HUVEC and that thiazolidinediones have a therapeutic potential for improving endothelial dysfunction observed in insulin resistance. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329404     DOI: 10.1006/bbrc.1999.0648

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

2.  Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques.

Authors:  Jonathan E Feig; Sajesh Parathath; James X Rong; Stephanie L Mick; Yuliya Vengrenyuk; Lisa Grauer; Stephen G Young; Edward A Fisher
Journal:  Circulation       Date:  2011-02-21       Impact factor: 29.690

3.  Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.

Authors:  M Artwohl; C Fürnsinn; W Waldhäusl; T Hölzenbein; G Rainer; A Freudenthaler; M Roden; S M Baumgartner-Parzer
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 4.  Vascular signaling pathways in the metabolic syndrome.

Authors:  Hiromi Rakugi; Kei Kamide; Toshio Ogihara
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

5.  Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

Authors:  Yoshiyuki Rikitake; James K Liao
Journal:  Circulation       Date:  2005-06-13       Impact factor: 29.690

6.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Authors:  Hongyu Zhang; Jharna Saha; Jaeman Byun; MaryLee Schin; Matthew Lorenz; Robert T Kennedy; Matthias Kretzler; Eva L Feldman; Subramaniam Pennathur; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

7.  The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.

Authors:  C M Werner; S H Schirmer; C Gensch; V Pavlickova; J Pöss; M B Wright; M Böhm; U Laufs
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

8.  Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.

Authors:  G-H Hao; X-L Niu; D-F Gao; J Wei; N-P Wang
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

Review 9.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance.

Authors:  Robert Kleemann; Marjan van Erk; Lars Verschuren; Anita M van den Hoek; Maud Koek; Peter Y Wielinga; Annie Jie; Linette Pellis; Ivana Bobeldijk-Pastorova; Thomas Kelder; Karin Toet; Suzan Wopereis; Nicole Cnubben; Chris Evelo; Ben van Ommen; Teake Kooistra
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.